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Mitochondrial dysfunction involving electron transport compo-
nents is implicated in the pathogenesis of several neurodegen-
erative disorders and is a critical event in excitotoxicity. Excitatory
amino acid L--N-oxalylamino-L-alanine (L-BOAA), causes pro-
gressive corticospinal neurodegeneration in humans. In mice,
L-BOAA triggers glutathione loss and protein thiol oxidation that
disrupts mitochondrial complex I selectively in motor cortex and
lumbosacral cord, the regions affected in humans. We examined
the factors regulating postinjury recovery of complex I in CNS
regions after a single dose of L-BOAA. The expression of thiol-
transferase (glutaredoxin), a protein disulfide oxidoreductase reg-
ulated through AP1 transcription factor was upregulated within 30
min of L-BOAA administration, providing the first evidence for
functional regulation of thioltransferase during restoration of mito-
chondrial function. Regeneration of complex I activity in motor
cortex was concurrent with increase in thioltransferase protein and
activity, 1 hr after the excitotoxic insult. Pretreatment with -lipoic
acid, a thiol delivery agent that protects motor neurons from
L-BOAA-mediated toxicity prevented the upregulation of thiol-
transferase and AP1 activation, presumably by maintaining thiol
homeostasis. Downregulation of thioltransferase using antisense
oligonucleotides prevented the recovery of complex I in motor
cortex and exacerbated the mitochondrial dysfunction in lumbo-
sacral cord, providing support for the critical role for thioltrans-
ferase in maintenance of mitochondrial function in the CNS.
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Excitotoxicity plays an important role in the pathogenesis of
neurodegenerative disorders (Tapia et al., 1999). Mitochondria
are critically involved in excitotoxic injury, accumulating large
amounts of calcium and generating reactive oxygen species
(Lopachin, 1999). Close association and synergistic interplay
exists between excitotoxicity, mitochondrial dysfunction, and
neurodegeneration. L--N-Oxalylamino-L-alanine (L-BOAA; syn-
onym, -N-oxalyl-,-diaminopropionic acid, -ODAP) is a non-
protein amino acid first isolated from the chickling pea obtained
from the plant Lathyrus sativus (Rao et al., 1964) grown in
drought-prone areas of Africa and Asia. Ingestion of the chickling
pea as a staple food leads to a progressive, neurodegenerative
disorder, neurolathyrism, a form of motor neuron disease (Selye,
1957) that involves upper motor neurons, degeneration of ante-
rior horn cells, and loss of axons in pyramidal tracts of lumbar
spinal cord (Streifler et al., 1977; Cohn and Streifler, 1981).
L-BOAA exerts its neurotoxicity through the AMPA subclass of
glutamate receptors (Pearson and Nunn, 1981; Ross et al., 1989).
Male mice show selective loss of rotenone-sensitive mitochon-
drial complex I activity (NADH ubiquinone 1 oxidoreductase) in
frontoparietal cortex (location of the motor cortex) and lumbo-
sacral segment of spinal cord after receiving a single dose of
L-BOAA, whereas other CNS and non-CNS tissues are unaf-
fected. The inhibitory effect of L-BOAA on complex I activity in
motor cortex and lumbosacral cord can be reversed in vitro by the
disulfide reductant dithiothreitol, indicating that the inhibition
occurs through oxidation of critical thiol groups in complex I
subunits (Sriram et al., 1998).
During oxidative stress, reduced glutathione (GSH) is oxidized
to glutathione disulfide (GSSG) in most non-CNS tissues, cells,
and organelles. In contrast, in brain (Shivakumar and Ravin-
dranath, 1992; Shivakumar et al., 1995) and brain mitochondria in
particular (Ravindranath and Reed, 1990), oxidative stress results
in extensive formation of protein–glutathione mixed disulfides at
available cysteine residues. Although glutathionylation of pro-
teins is seen in certain cells of non-neural origin (Schuppe et al.,
1992; Rokutan et al., 1994), it is more pronounced in brain,
presumably because extrusion of GSSG, as routinely observed in
other tissues such as lung and liver, is not always seen in brain
(Ravindranath and Reed, 1990; Shivakumar et al., 1995).
Thiol-disulfide oxidoreductases comprise a class of enzyme
that is primarily involved in catalysis of thiol-disulfide inter-
change reactions. This includes thioltransferase (glutaredoxin),
thioredoxin, and protein disulfide isomerase (Holmgren, 1989;
Wells et al., 1993). Thioltransferase was initially discovered as a
glutathione-dependent electron donor for ribonucleotide reduc-
tase in mutants lacking thioredoxin (Holmgren, 1976, 1979).
Whereas thioredoxin and protein disulfide isomerase have broad
substrate specificities (Mieyal et al., 1995) thioltransferase uses
glutathione and specifically reduces glutathione-containing mixed
disulfides with greater efficiency than does thioredoxin (Gravina
and Mieyal, 1993; Chrestensen et al., 2000). Thioltransferase is a
low molecular weight protein (12 kDa; Gan and Wells, 1986;
Mieyal et al., 1991), and recombinant human thioltransferase
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expressed and purified from Escherichia coli is identical to the
natural enzyme (Chrestensen et al., 1995). Because thioltrans-
ferase is expressed constitutively in rat (Balijepalli et al., 1999)
and human brain (Balijepalli et al., 2000), we examined its pos-
sible involvement in recovery of complex I activity after excito-
toxic insult by L-BOAA.
MATERIALS AND METHODS
Materials. L-BOAA was obtained from Research Biochemicals (Natick,
MA). Cysteinyl-glutathione disulfide was purchased from Toronto Re-
search Chemicals (Toronto, Canada). TRI reagent was purchased from
Molecular Research Center (Cincinnati, OH). Pure thioltransferase and
antiserum to human red blood cell (RBC) thioltransferase were gifts of
Prof. J. J. Mieyal (Case Western Reserve University, Cleveland, OH).
Ubiquinone 1 was obtained from Eisai (Tokyo, Japan). Northern blot
analysis was performed using digoxigenin-labeling kit from Boehringer
Mannheim (Mannheim, Germany). Immunohistochemistry was per-
formed using Vectastain ABC kit from Vector Laboratories (Burlin-
game, CA). Antibody to p-c-Jun, cJun, JunB, cFos, FosB and Fra-1 were
purchased from Santa Cruz Biotechnology (Santa Cruz, CA). All other
chemicals and reagents were of analytical grade and were obtained from
Sigma (St. Louis, MO) or Qualigens (India).
Animals. Male Swiss albino mice (3–4 months old, 25–30 gm) were
obtained from the National Institute of Mental Health and Neuro-
sciences Animal Research Facility. Animals had ad libitum access to
pelleted diet (Lipton, Calcutta, India) and water. All animal experiments
were performed according to National Institutes of Health guidelines for
care and use of laboratory animals. All efforts were made to minimize
animal suffering, to reduce number of animals used, and to use alterna-
tives to in vivo techniques, if available.
L-BOAA was dissolved in normal saline (10 mg/kg body weight) and
administered subcutaneously to mice. In some experiments, -lipoic acid,
a thiol antioxidant (20 mg/kg body weight, s.c.) was given 1 hr before
L-BOAA treatment. Control animals received vehicle alone. Animals
were killed at specified times, and brain and spinal cord were removed.
The motor cortex was dissected from the brain (Sriram et al., 1998), the
spinal cord was exposed, and thoracic and lumbosacral segments of the
cord were harvested.
Processing of tissue. Tissues were removed immediately and processed
for measurement of complex-I and thioltransferase activities and for
estimation of glutathione and protein mixed glutathione disulfide levels.
Tissue was homogenized in 0.25 M sucrose and centrifuged at 1000  g
for 10 min to obtain the postnuclear supernatant; it was again centrifuged
at 14,000  g for 30 min to obtain the mitochondrial pellet. The yield of
mitochondrial protein from lumbosacral cord and motor cortex of mice
was 250–400 g. The postmitochondrial supernatant was used for esti-
mation of thioltransferase activity and immunoblot analysis. The mito-
chondrial pellet was suspended in sucrose (0.25 M) and freeze-thawed for
the assay of complex I. For the assay of GSH and protein glutathione
mixed disulfide (PrSSG) tissues were frozen immediately in liquid nitro-
gen, weighed, and homogenized in nine volumes of 100 mM potassium
phosphate buffer, pH 7.4, containing 1 mM EDTA. An aliquot of homog-
enate was added to equal volume of 5-sulfosalicylic acid (1%, w/v),
mixed, and centrifuged at 10,000  g for 10 min, the supernatant was
used for GSH estimation, and the acid-precipitated pellet was used for
estimation of protein mixed glutathione disulfides.
Assay of NADH:ubiqninone oxidoreducatase (Complex I). Complex I
was assayed in mitochondrial preparations as rotenone-sensitive NADH-
ubiqinone oxidoreductase (Sriram et al., 1997). The assay was performed
in 35 mM potassium phosphate buffer, pH 7.4, containing sodium cyanide
(2.65 mM), magnesium chloride (5 mM), EDTA (1 mM), bovine serum
albumin (1 mg/ml), and antimycin (2 g/ml). Brain mitochondria (70–80
g) and ubiquinone 1 (0.05 mM) were added to the assay buffer to a final
volume of 0.48 ml. After preincubation of the reaction mixture at room
temperature for 2 min, the reaction was initiated by addition 0.02 ml of
5 mM NADH solution. Test and blank reactions were run separately
using a single beam spectrophotometer. The rate of decrease of absor-
bance at 340 nm (0.04–0.09/min) was monitored over 3 min. The assay
was also performed in the presence of rotenone to determine the
rotenone-sensitive enzyme activity that was 80% of the total activity.
The enzyme activity was expressed as nanomoles of NADH oxidized per
minute per milligram of protein.
Assay of thioltransferase. Thioltransferase activity was estimated in
postmitochondrial supernatant using cysteinyl-glutathione disulfide as
substrate, according to Balijepalli et al. (1999). The postmitochondrial
supernatant from brain region or spinal cord was suspended in 0.11 M
potassium phosphate buffer, pH 7.4, containing 0.5 mM GSH, 24 U/ml
glutathione reductase, and 3.5 mM NADPH. The reaction was initiated
by addition of the substrate cysteinyl-glutathione disulfide (100 mM). The
decrease in absorbance of NADPH at 340 nm was measured for 3 min.
Blanks were run simultaneously without addition of postmitochondrial
supernatant. The net enzymatic rate was obtained by subtraction of
nonenzymatic rate from total rate. The enzyme activity was expressed as
nanomoles of NADPH oxidized per minute per milligram of protein.
The protein concentration was estimated by a dye-binding method (Brad-
ford, 1976).
Estimation of glutathione. Total glutathione (GSH  GSSG) was esti-
mated by the enzymatic recycling method (Tietze, 1969). The reaction
mixture consisted of 100 mM potassium phosphate buffer, pH 7.4, con-
taining 0.8 mM dithiobisnitrobenzoic acid and 0.5 U/ml glutathione
reductase in a total volume of 0.44 ml. The acid-soluble tissue superna-
tant (0.01 ml) prepared as described above was added. The reaction was
initiated by adding 0.05 ml of 1.2 mM NADPH. The increase in absor-
bance was measured at 412 nm over 3 min. A standard curve was
generated using known amount of GSSG.
Estimation of protein glutathione mixed disulfides. The acid-precipitated
pellet from CNS regions was washed with ethanol (2  1 ml) and
sonicated for 5 min. The pellet was resuspended in 50 mM 4-morpholine-
propane sulfonic acid buffer, pH 8.0, containing dithiothreitol (25 mM).
The suspension was sonicated for 10 min and incubated in a shaker water
bath for 1 hr at 37°C. Samples were deproteinized with 70% perchloric
acid and centrifuged at 8000 rpm for 10 min. An aliquot of the super-
natant was treated with o-pthaldialdehyde and reaction was kept in the
dark for 10 min. The fluorescence was recorded after excitation at 350
nm and emission at 420 nm (Akerboom and Sies, 1981; Ravindranath
and Reed, 1990). A standard curve of GSH was also run simultaneously.
The levels of GSH, GSSG, and PrSSG were validated by HPLC (Reed et
al., 1980).
Immunoblot analysis. Pure thioltransferase (Mieyal et al., 1991) and
postmitochondrial supernatant from the motor cortex and lumbosacral
cord of vehicle- and L-BOAA-treated mice were subjected to SDS-PAGE
gel electrophoresis, transferred to nitrocellulose membrane, and incu-
bated with the antibody to human RBC thioltransferase (Mieyal et al.,
1991), followed by incubation with anti-rabbit IgG labeled with alkaline
phosphatase (Balijepalli et al., 1999). The immunostained bands were
detected using nitroblue tetrazolium and 5-bromo-4-chloro-3-indolyl
phosphate as chromogens.
Northern blotting. Total RNA from motor cortex and lumbosacral cord
of vehicle and L-BOAA-treated mice was extracted using TRI reagent
(Chomczynski, 1993). CNS regions from three animals were pooled for
each sample preparation. Total RNA was separated electrophoretically
and transferred to positively charged nylon membranes by capillary
transfer, UV cross-linked, and hybridized with digoxigenin-labeled
cRNA, prepared using the cDNA to brain thioltransferase (Balijepalli et
al., 1999). The blots were washed, incubated with antibody to digoxigenin
conjugated with alkaline phosphatase, and bands were visualized using
chromogenic substrate for alkaline phosphatase.
In situ hybridization. Vehicle and L-BOAA-treated male Swiss albino
mice were anesthetized with ether and perfused transcardially with
normal saline followed by 4% paraformaldehyde (w/v) before the re-
moval of the brain and spinal cord. Vibratome sections (20-m-thick)
were cut in the coronal plane at the level of motor cortex and lumbar cord
under RNase-free conditions. The sections were processed for in situ
hybridization using digoxigenin-labeled sense and antisense cRNA
probes, synthesized from cDNA to brain thioltransferase. After hybrid-
ization, the sections were washed and incubated with blocking reagent
followed by antibody to digoxigenin conjugated to horseradish peroxi-
dase and stained using diaminobenzidine and hydrogen peroxide for light
microscopic observations.
Immunohistochemistry. Vibratome sections (30-m-thick) from vehicle-
and L-BOAA-treated mice were prepared as above and processed for
immunohistochemical analysis using ABC Elite kit (Vector Laboratories),
per the manufacturer’s instructions. Sections were incubated with anti-
serum to human RBC thioltransferase (1:250 dilution in PBS) followed by
incubation with biotinylated anti-rabbit IgG and avidin–biotin–peroxidase
complex and visualized using diaminobenzidine and hydrogen peroxide.
Electrophoretic mobilit y shif t assays. Nuclear extracts were prepared
from motor cortex and lumbosacral cord from vehicle-treated, L-BOAA-
and -lipoic acid-treated, and L-BOAA-treated mice according to Korner
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et al. (1989). CNS regions from three animals were pooled for each
sample preparation. The tissue was suspended in 10 mM HEPES, pH 7.9,
containing 1.5 mM magnesium chloride, 10 mM potassium chloride, 0.5
mM phenylmethylsulfonyl fluoride, 1 g/ml pepstatin A, 10 g/ml leu-
peptin, and 10 g/ml aprotinin and homogenized using a Dounce ho-
mogenizer. The samples were centrifuged at 1000 g for 10 min, and the
pellet was resuspended in 20 mM HEPES, pH 7.9, containing 0.84 M
sodium chloride, 1.5 mM magnesium chloride, 0.4 mM EDTA, 0.5 mM
dithiothreitol, and the above-mentioned protease inhibitors, incubated
for 30 min at 4°C, and centrifuged at 14,000  g for 15 min. Aliquots of
the supernatant containing the nuclear extract were frozen in liquid
nitrogen and used for electrophoretic mobility shift assay.
Electrophoretic mobility shift and supershift assays were performed
using the following consensus oligonucleotides: 5-GATCGAGGGG
ACTTTCCCTAGC-3 and 3-CTAGCTCCCCTGAAAGGGATCG-5
(NFkB); 5-CTAGTGATGAGTCAGCCGGATC-3 and 3-GATCAC
TACTCAGTCGGCCTAG-5 (AP-1); and 5-CGCGGGGCGCGTGA
CTATGCGTGGGCTGGA-3 and 3-GCGCCCCGCGCACTGATA
CGCACCCGACCT-5 (ARE). Oligonucleotides were labeled with
-[ 32P]ATP using polynucleotide kinase. Nuclear extracts were sus-
pended in DNA binding buffer containing 10 mM Tris, pH 7.5, 20 mM
potassium chloride, 1 mM EDTA, 1 mM -mercaptoethanol, 4% (v/v)
glycerol, and protease inhibitors as mentioned before and incubated with
each radiolabeled probe for 30 min at room temperature. Bound and free
probes were separated by electrophoresis on a polyacrylamide gel in 44.5
mM Tris buffer, pH 8.0, containing 44.5 mM borate and 1 mM EDTA. Gels
were dried under vacuum, and radioactivity was detected using a Phos-
phorImager. Band specificity was determined by adding 50 M excess of
unlabeled probe to the nuclear extract before adding labeled probe. For
supershift assays, nuclear extracts were incubated overnight with the
specified antibody at 4°C before adding labeled oligonucleotides.
Downregulation of thioltransferase expression using antisense oligonucle-
otides. Phosphorothionate end-capped oligonucleotides (21 mer) origi-
nating from the start codon of thioltransferase cDNA (antisense: ATG
GCT CAG GAG TTT GTG AAC; sense: TAC CGA GTC CTC AAA
CAC TTA) were injected intrathecally into mice at 100 g/dose, twice at
12 hr intervals. The downregulation of thioltransferase was examined by
immunoblot analysis and enzyme activity measurement 12 hr after the
last injection of oligonucleotides. L-BOAA (10 mg/kg body weight) was
administered 11 hr after the second injection of the end-capped oligo-
nucleotides, and the animals were killed 1 hr after L-BOAA dosing. The
motor cortex, thoracic, and lumbosacral segments of the spinal cord were
dissected out, and the activities of complex I and thioltransferase were
assayed as described earlier.
Statistical analysis was performed using Student’s t test or ANOVA
followed by Student–Newman–Keuls or Dunnett’s test as appropriate.
RESULTS
In the motor cortex (Fig. 1a) there was a significant decrease in
GSH levels at 0.5 and 1 hr after L-BOAA treatment that was
accompanied by concomitant increase in PrSSG levels; both GSH
and PrSSG levels recovered and were similar to control levels at
4 hr. The depleted GSH in both the CNS regions was recovered
essentially as PrSSG and significant increase in GSSG levels was
not seen as measured by HPLC (data not shown). Mice treated
with L-BOAA showed a sustained decrease in GSH levels and
increase in PrSSG levels up to 4 hr in the lumbosacral segment of
the spinal cord (Fig. 1b). The amount of GSH gained in lumbo-
sacral cord as PrSSG at 0.5, 1, and 4 hr after a single dose of
BOAA was 133, 150, and 82% over and above the levels observed
in control, respectively, whereas in the motor cortex, the levels
were 140 and 121% at 0.5 and 1 hr, respectively. At the end of 4
hr, both GSH and PrSSG were restored to control levels in the
motor cortex (Fig. 1a) but not in the lumbosacral cord. The total
GSH recovered (sum of GSH equivalents recovered as GSH and
PrSSG) at 1 hr in motor cortex compared with vehicle-treated
controls was 112% of control (Fig. 1a). In the lumbosacral cord,
total GSH recovered was significantly greater than control
(119%) at 1 hr (Fig. 1b).
The differential response to the thiol perturbation in the lum-
bosacral cord and motor cortex was also reflected in the mito-
chondrial complex I activity after L-BOAA administration.
Whereas a persistent decrease from 0.25–4 hr was seen in com-
plex I activity in the lumbosacral cord (Fig. 2, LSC), a significant
decrease was seen in the motor cortex at 0.5 hr after L-BOAA
administration, and the enzyme activity rebounded to 125% of
the control activity at 1 hr (Fig. 2, MC). Because we had earlier
observed that the inhibition of complex I activity was caused by
protein thiol oxidation that could be restored in vitro by the
disulfide reductant dithiothreitol (Sriram et al., 1998), we simul-
taneously examined the activity of thioltransferase in the CNS
regions after L-BOAA treatment. Thioltransferase activity was
increased and sustained by at least twofold in the motor cortex
1–4 hr after L-BOAA administration, thus paralleling the recov-
ery of complex I in the motor cortex. In the lumbosacral cord,
thioltransferase activity was increased significantly at 1 and 4 hr
Figure 1. GSH and PrSSG levels in motor cortex (a) and lumbosacral
cord ( b) at various periods after a single dose of L-BOAA. L-BOAA (10
mg/kg body weight, s.c.) was administered to mice, and animals were
killed after 0.5, 1, and 4 hr (black bars). Control animals received vehicle
alone (white bars). GSH and PrSSG levels were estimated and are de-
picted as a percentage of corresponding controls. Total GSH recovered
(sum of GSH equivalents recovered as GSH and as PrSSG) is also
depicted. Values are mean  SD (n  3 animals). GSH levels in motor
cortex and lumbosacral cord from control animals were 22.51  0.823 and
21.41  2.311 nmol/mg protein (equivalent to 1.54  0.017 and 1.38 
0.168 mol of GSH/gm tissue), respectively. PrSSG levels in motor cortex
and lumbosacral cord of control animals were 1.71  0.076 and 3.07 
0.135 nmol of GSH equivalents/mg protein (equivalent to 0.189  0.083
and 0.203  0.048 mol of GSH equivalents/gm tissue), respectively.
Asterisks indicate values significantly different from corresponding con-
trols ( p  0.05).
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after L-BOAA administration (44.5 and 55.3% higher than con-
trols, respectively), but the increase was considerably lower com-
pared with motor cortex and was not accompanied by recovery of
complex I in the lumbosacral cord. In the thoracic segment of the
spinal cord, which is unaffected by L-BOAA treatment, no change
in GSH levels, complex I, and thioltransferase activities was
observed as compared with vehicle-treated controls (data not
shown).
To determine if the increase in thioltransferase activity was
associated with increased expression of protein, immunoblot
analysis was performed using antiserum to human RBC thiol-
transferase, which shares 100% homology with the brain thiol-
transferase (Chrestensen et al., 1995). Both the immunoblot anal-
ysis and immunohistochemistry revealed increased expression of
thioltransferase protein (Fig. 3a,b). Although the thioltransferase
activity in the motor cortex was increased to a greater extent than
in the lumbar cord (Fig. 2), the immunoblot analysis seemed to
indicate similar increase in thioltransferase protein in both the
CNS regions. This may be attributable to the fact that the thiol-
transferase protein detected in the immunoblot would represent
both the active form of the enzyme as well as the oxidized form
of the enzyme containing disulfide groups. In the lumbar cord,
there is sustained decrease in GSH levels and increase in protein
glutathione mixed disulfides (Fig. 1) as compared with motor
cortex. Increased protein immunostaining was seen in the neu-
rons in the motor cortex and in the anterior horn cells in the
lumbar cord (Fig. 3b) 1 hr after administration of L-BOAA. This
was associated with an upsurge in the transcription of thioltrans-
ferase mRNA as examined by Northern blotting (Fig. 4a) and in
situ hybridization (Fig. 4b), 0.5 hr after the administration of
L-BOAA. Immunohistochemical localization and in situ hybrid-
ization experiments revealed increases in thioltransferase protein
and mRNA in motor cortex neurons and anterior horn cells of the
lumbar cord, the cells which are most affected by chronic
L-BOAA treatment (Sriram et al., 1998).
-Lipoic acid, a thiol delivery agent, helps restore thiol ho-
meostasis in brain (Panigrahi et al., 1996). Therefore, we exam-
ined the effect of pretreatment with -lipoic acid on L-BOAA-
induced upregulation of thioltransferase. Administration of
-lipoic acid (20 mg/kg body weight), 1 hr before L-BOAA,
abolished complex I inhibition in the lumbosacral cord (Fig. 5a).
Furthermore, this pretreatment prevented the increase in expres-
sion of thioltransferase protein in the motor cortex usually seen
after L-BOAA administration (Fig. 5b), although the activity of
the enzyme showed a significant increase in the motor cortex (Fig.
Figure 2. Complex I (a) and thioltransferase (b) activities in the motor
cortex (MC) and lumbosacral cord (LSC) at various periods after a single
dose of L-BOAA. Mice were administered L-BOAA (10 mg/kg body
weight, s.c.) and killed at indicated times. The control values were similar
at all time points examined and are indicated as the zero hour value.
Values are mean SEM (n 6 animals). Complex I activity is expressed
as nanomoles of NADH oxidized per minute per milligram of protein,
and thioltransferase activity is expressed as nanomoles of NADPH oxi-
dized per minute per milligram of protein. Asterisks indicate values
significantly different from corresponding controls ( p  0.05).
Figure 3. Expression of thioltransferase protein in mouse CNS after
L-BOAA treatment. Mice were killed 1 hr after L-BOAA administration.
a, A representative blot from motor cortex (MC) and lumbosacral cord
(LSC) from control (C) and L-BOAA treated (T) animals subjected to
immunoblot analysis using antiserum to thioltransferase (lanes contained
10 g of protein). A sample of pure thioltransferase (P, 10 ng) was also
loaded on the same gel. Densitometric analysis of the immunoblots
representing the relative intensity of the immunoreactive bands from
control (black bars) and L-BOAA-treated animals ( gray bars) are repre-
sented. Values are mean  SD (n  3 animals). Asterisks indicate values
significantly different from corresponding control ( p  0.05). b, Immuno-
histochemical localization of thioltransferase in motor cortex and lumbar
cord revealed the increased levels of thioltransferase in the neurons in layer
3 of motor cortex (BOAA-MC) and the anterior horn cells of the lumbar
cord (BOAA-LSC) as compared with untreated animals (CON-MC and
CON-LSC) 1 hr after a single dose of L-BOAA. Scale bar, 25 m.
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5a) of animals treated with -lipoic acid alone or with both
-lipoic acid and L-BOAA, indicating that the increase in activity
was presumably caused by post-translational effects such as main-
tenance of reduced thiol status of the enzyme.
Because a consensus sequence to the AP1 binding site is known
to exist upstream of the thioltransferase gene, we examined the
effect of L-BOAA on activation of AP1. In addition, we examined
the activation of the transcription factors ARE and NFB that
are activated under oxidative stress (Radjendirane and Jaiswal,
1999; Zhou et al., 2002). Within 15 min after the administration
of L-BOAA, significant increases in binding of AP1 and ARE
(which share consensus binding sites) were observed in the motor
cortex and lumbosacral cord (Fig. 6a,b), whereas NFB was
unaffected (Fig. 6c). Pretreatment of animals with -lipoic acid
prevented L-BOAA activation of both AP1 and ARE. The acti-
vation of AP1 was supershifted by antibody to phosphorylated
cJun (Fig. 6d), but was unaffected by antibody to JunB, cFos,
FosB, and Fra-1 (data not shown). Thus, within 15 min after
L-BOAA administration, activation of transcription factor AP1
occurred, followed within 30 min by increased transcription of
thioltransferase mRNA, and within 1 hr after L-BOAA adminis-
Figure 4. Expression of thioltransferase mRNA in mouse CNS after
L-BOAA treatment. Mice were administered L-BOAA and killed 0.5 hr
after L-BOAA. a, A representative Northern blot of the total RNA from
motor cortex (lanes 1, 2; 10 g) and lumbosacral cord (lanes 3, 4; 10 g)
from control (lanes 1, 3) and treated (lanes 2, 4 ) animals, respectively,
subjected to Northern blot analysis using cRNA to brain thioltransferase
(TTase). The blots were also hybridized with -actin cRNA for normal-
ization. Densitometric analyses of the Northern blots representing the
relative intensity of the hybridized bands from -actin (black bars) and
thioltransferase (white bars) are represented. Values are means of two
individual experiments using pooled brain regions from three animals. b, In
situ hybridization of thioltransferase mRNA in motor cortex and lumbar
cord revealed increased levels of thioltransferase in the neurons in layer 3
of motor cortex (BOAA-MC) and the anterior horn cells of the lumbar
cord (BOAA-LSC) as compared with untreated animals (CON-MC and
CON-LSC) 0.5 hr after L-BOAA. Scale bar, 25 m.
Figure 5. Effect of -lipoic acid pretreatment on L-BOAA-mediated
inhibition of complex I activity and upregulation thioltransferase in
mouse CNS. Animals were pretreated with -lipoic acid (20 mg/kg body
weight, s.c.) 1 hr before administration of L-BOAA (10 mg/kg body
weight, s.c.) and killed 1 hr after the L-BOAA dose. a, Activities of
complex I and thioltransferase were measured in the motor cortex and
lumbosacral cord as described under Figure 1. Values are mean  SD
(n  6 animals, and asterisks indicate values significantly different from
vehicle-treated controls) ( p  0.05). b, A representative blot from motor
cortex (10 g) of animals treated with vehicle (lane 2), L-BOAA (lane 3),
-lipoic acid (lane 4 ), and -lipoic acid and L-BOAA (lane 5) subjected to
immunoblot analysis using antiserum to thioltransferase. A sample of pure
thioltransferase (lane 1, 10 ng) was also loaded on the same gel. Densito-
metric analyses of immunoblots representing relative intensity of immuno-
reactive bands are represented. Values are mean of two individual
experiments.
8406 J. Neurosci., October 1, 2002, 22(19):8402–8410 Kenchappa et al. • Thioltransferase, Mitochondria, and Excitotoxicity
tration, by the increased expression of thioltransferase protein
and activity.
To further confirm the role of thioltransferase in the recovery
of complex I after L-BOAA administration, we administered
antisense oligonucleotides to downregulate thioltransferase, and
we examined the effect on the recovery of mitochondrial function.
The oligonucleotides were injected intrathecally to ensure the
selective downregulation of thioltransferase in the CNS. Injection
of 200 g of antisense oligonucleotides in two divided doses of
100 g at 12 hr intervals resulted in the downregulation of
thioltransferase expression in the motor cortex (42%) and lum-
bosacral cord (46%) at 12 hr after the last injection (Fig. 7a,b).
The sense oligonucleotides had no effect on the enzyme activity.
L-BOAA was administered 11 hr after the second injection of
oligonucleotides to three sets of animals: vehicle-treated, sense, or
antisense oligonucleotide-treated, and the animals were killed 1
hr later. This time period of L-BOAA exposure was chosen,
Figure 6. Activation of transcription factors AP1 (a), ARE (b), and
NF-B (c) after administration of L-BOAA to mice. Mice were admin-
istered L-BOAA and killed 15 min after L-BOAA. Electrophoretic mo-
bility shift assays were performed using nuclear extracts (5 g of protein)
from motor cortex (MC) and lumbar sacral cord (LSC) of mice treated
with vehicle (C), L-BOAA (B), and -lipoic acid and L-BOAA (A).
Densitometric analyses of the shifted bands representing the relative
intensity of binding of transcription factors are represented. Values are
mean of three individual experiments. d, Antibody to phosphorylated
cJun super shifts the mobility of the transcription factors AP1 after
administration of L-BOAA to mice. The nuclear extracts from motor
cortex (MC; lanes 1–3) and lumbar sacral cord (LSC; lanes 4–6 ) of mice
treated with vehicle (lanes 1, 4 ) and L-BOAA (lanes 2, 3, 5, 6 ) were
preincubated with antibody to phosphorylated c Jun before performing
electrophoretic mobility shift assay as described above.
Figure 7. Effect of downregulation of thioltransferase protein using
antisense oligonucleotides on L-BOAA-mediated mitochondrial dysfunc-
tion. Mice were injected intrathecally with sense and antisense oligonu-
cleotides and killed 12 hr after the last injection. a, Immunoblot analysis
of thioltransferase protein from motor cortex (lanes 2–4 ) and lumbosacral
cord (lanes 5–7 ) from vehicle (lanes 2, 5), sense oligonucleotide-treated
(lanes 3, 6 ), and antisense oligonucleotide-treated (lanes 4, 7 ) immuno-
stained with antiserum to RBC thioltransferase (lanes contained 10 g of
protein). Lane 1 contained 10 ng of pure thioltransferase. b Represents
the densitometric analysis of the immunoblots from three animals. Values
are mean  SD (n  3 animals). c, Thioltransferase and complex I
activities in motor cortex (MC), lumbosacral cord (LSC), and thoracic
cord (TC) of animals treated with sense or antisense oligonucleotides (as
described above) followed by L-BOAA administration and killed after 1
hr. Values are mean  SD (n  5–6) animals. Asterisks indicate values
significantly different from vehicle-treated control ( p  0.05).
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because the rebound in complex I activity is seen in the motor
cortex 1 hr after L-BOAA, and the effect of downregulation of
thioltransferase on the recovery of complex I could be examined.
Thioltransferase and complex I activity was measured in the
motor cortex, lumbosacral cord, and the thoracic cord, which is
unaffected by L-BOAA. Antisense oligonucleotides completely
abolished the recovery of complex I in the motor cortex that
otherwise would have occurred within 1 hr after L-BOAA admin-
istration, whereas the sense nucleotides had no significant effect.
Downregulation of thioltransferase by itself (without L-BOAA
challenge) resulted in significant inhibition of complex I both in
motor cortex and lumbosacral cord (Fig. 7c), indicating the crit-
ical role of this enzyme in maintaining mitochondrial function. In
the lumbosacral cord, antisense oligonucleotides further inhibited
complex I as compared with L-BOAA alone. Mitochondrial func-
tion in the thoracic cord was unaffected by L-BOAA, and there
was no significant difference between the groups of animals
treated with the vehicle, sense, or antisense oligonucleotides as
compared with those treated additionally with L-BOAA. How-
ever, complex I activity was significantly decreased in the anti-
sense oligonucleotide-treated group, similar to that seen in motor
cortex and lumbosacral cord (Fig. 7c).
DISCUSSION
Chronic administration of L-BOAA to mice for 40 d results in cell
loss in motor cortex and lumbosacral cord (Sriram et al., 1998). In
the present study we administered a single dose of L-BOAA that
does not cause any detectable irreversible damage to neuronal
cells to study early events after exposure to the excitotoxin.
We demonstrate herein that the rebound of complex I (125% of
control level) in the motor cortex after the initial inhibition
caused by L-BOAA is associated with up-regulation of thioltrans-
ferase. The increase in thioltransferase activity was specific to the
motor cortex and lumbosacral cord (where complex I is inhibited
by L-BOAA), whereas it was unchanged in the thoracic cord (the
CNS region unaffected by L-BOAA). The cascade of events that
occurs after a single subcutaneously administered dose of
L-BOAA consists of activation of the transcription factor AP1,
mediated through phosphorylated cJun, within 15 min, followed
by upregulation of thioltransferase mRNA by 30 min, and in-
crease in the thioltransferase protein, both in the motor cortex
and lumbosacral segment of the spinal cord, within 1 hr. The
degree of upregulation of thioltransferase was substantially
greater in motor cortex as compared with the lumbosacral cord
(Figs. 2–4). Furthermore, the 2.5-fold increase in thioltransferase
activity in motor cortex was accompanied by full rebound of
complex I activity. In the lumbosacral cord the increase in thio-
ltransferase was less (1.5-fold), and the complex I activity did not
fully recover to control levels, possibly because of an insufficient
upregulation of thioltransferase. Additionally, there was sus-
tained loss of GSH in the lumbosacral cord up to 4 hr after the
single dose of L-BOAA, whereas in motor cortex there was only
a transient loss of the tripeptide (Fig. 1). In the motor cortex, thiol
homeostasis was restored within 4 hr while there was sustained
perturbation in the lumbosacral cord (Fig. 1). Sustained loss of
GSH can lead to inactivation of protein, including thioltrans-
ferase, through glutathionylation. GSH is essential for thioltrans-
ferase activity; indeed, deprivation of cellular GSH results in
decreased thioltransferase activity (Chrestensen et al., 2000).
Thus, lowered levels of GSH in lumbosacral cord could be re-
sponsible for attenuation of the upregulation of thioltransferase.
Loss of cellular GSH was shown to have a direct effect on
complex I activity in pheochromocytoma cell line 12 cells treated
with buthionine sulfoximine (Davey et al., 1998). Additionally,
downregulation of GSH through doxycycline-mediated induction
of antisense messages against -glutamyl-cysteine synthetase (the
rate-limiting enzyme in GSH synthesis) results in loss of mitochon-
drial GSH and decreased mitochondrial function through selective
inhibition of complex I (Jha et al., 2000). Complex I has several
cysteine residues in its active site (Dupuis et al., 1991), and the
facile glutathionylation of thiol groups therein by oxidative stress
can potentially result in inhibition of the enzyme.
The preferential and often reversible S-glutathionylation of
proteins that occurs during oxidative stress has been suggested to
be a protective mechanism in brain (Ehrhart and Zeevalk, 2001).
Thioltransferase efficiently and selectively reduces protein gluta-
thione mixed disulfides to protein thiols in the presence of GSH
(Mieyal et al., 1995). We hypothesized that since formation of
protein glutathione mixed disulfides is one of the major conse-
quences of oxidative stress in brain, thioltransferase could po-
tentially play an important role during neuronal recovery from
oxidative stress by restoring protein thiol homeostasis. We, there-
fore, examined the regulation of thioltransferase during recovery
of mitochondrial function after an excitotoxic insult and discov-
ered its upregulation. Although the enzymatic function of thiol-
transferase was discovered more than 25 years ago (Mannervik
and Axelsson, 1975) and its potential role in repair of oxidative
damage has been postulated (Holmgren, 1989; Mieyal et al.,
1995), the present study provides the first evidence for its differ-
ential regulation at the transcriptional level during CNS recovery
from oxidative stress. Thus, presumably after a perturbation in
the thiol status, the transcription of thioltransferase mRNA is
upregulated within a relatively short time after a systemic dose of
L-BOAA. Upstream of the thioltransferase gene there is an AP1
transcription factor binding site, and transfection of this promoter
region along with a luciferase reporter results in higher luciferase
activity, indicating that transcription of thioltransferase is medi-
ated through AP1 (Park and Levine, 1997). We examined AP1-
mediated transcription and found it to be activated within 15 min
of L-BOAA administration, after which the sequential upregula-
tion of thioltransferase mRNA and protein occurred (Figs. 2–4).
It has been suggested that thioltransferase might regulate the
transcriptional activity of AP1 through activation of the Jun
N-terminal kinase (JNK) cascade (Daily et al., 2001), thereby
protecting cerebellar granule neurons in culture. Activation of the
JNK signaling cascade that converges on the phosphorylation of
cJun has also been associated with the induction of apoptosis in
MPTP-treated mice (Xia et al., 2001). However, in the present
study we show that within 15 min after a single systemic admin-
istration of the excitatory amino acid, L-BOAA, the phosphory-
lation of cJun and its translocation to the nucleus occurs and is
accompanied by activation of AP1, leading to increased transcrip-
tion of thioltransferase mRNA. The experiments using antisense
oligonucleotides provided further confirmation of thioltrans-
ferase involvement in the functional recovery of protein thiols
after oxidative insult. Treatment with thioltransferase antisense
oligonucleotides alone resulted in significant decrease in complex
I activity in all the three CNS regions examined, including the
thoracic cord which is unaffected by L-BOAA, indicating the
important role played by thioltransferase in the maintenance of
mitochondrial function. Although the critical role played by GSH
in maintaining complex I activity has been demonstrated earlier,
this is the first evidence demonstrating the importance of thiol-
transferase in maintaining mitochondrial complex I function,
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presumably through the regeneration of thiol moiety that undergo
glutathionylation.
The majority of cellular thioltransferase (Grx1) is localized in
the cytosol, however recently a mitochondrial form of thioltrans-
ferase (Grx2; Gladyshev et al., 2001; Lundberg et al., 2001) has
been reported that shares very little sequence identity to Grx1,
and their antibodies do not cross-react. The antisense oligonucle-
otide sequence used in the present study to downregulate Grx1
shared no homology with Grx2. The cDNA and antibody used in
the present study correspond to the cytosolic form of thioltrans-
ferase Grx1 (Chrestensen et al., 1995). However, a portion of the
cytosolic form of thioltransferase (Grx1) also has been found in
isolated rat heart mitochondria (Vazquez et al., 2001). Further-
more, an analogous finding that a fraction of the yeast cytosolic
Cu-Zn superoxide dismutase is localized to the intermembrane
space of mitochondria was reported recently (Sturtz et al., 2001).
Thus, the transcriptional upregulation of thioltransferase seen in
the present study might represent the Grx1 present in both
cytosol and mitochondria.
Complex I abnormalities have also been observed in other
neurodegenerative disorders. Earlier studies using MPTP, a neu-
rotoxin that causes Parkinson-like symptoms in primates, have
helped to identify abnormalities in complex I in mitochondria
from platelets, brain, and muscle of Parkinson’s disease patients
(Parker et al., 1989; Mizuno et al., 1995). There is evidence that
mitochondrial complex I dysfunction is a consequence of stress
oxidation of critical thiol groups in the enzyme (Sriram et al.,
1997, 1998; Jha et al., 2000). In addition, inhibition of complex I
activity mediated by a single dose of MPTP can be reversed in
vitro by treatment of brain mitochondria with the disulfide reduc-
tant dithiothreitol, indicating that thiol oxidation may be a pri-
mary cause for loss in activity, although complex I activity may
not be reversible in chronic models of MPTP toxicity (Annepu
and Ravindranath, 2000). Thus, the implications of the present
results might be extendable to complex I abnormalities seen in
animal models of Parkinson’s disease, where also thioltransferase
may play a key role in recovery of mitochondrial function.
Whereas upregulation of thioltransferase leads to recovery
from mitochondrial injury after subacute insult, sustained up-
regulation of the enzyme may be required to prevent the damage
that occurs after chronic insult. Another approach for protection
of mitochondria during chronic insult could potentially involve
the use of thiol delivery agents such as -lipoic acid. As shown in
the present study, previous treatment with -lipoic acid not only
prevents mitochondrial dysfunction but also abolishes the early
response of AP1 activation after L-BOAA administration. Fur-
thermore, administration of -lipoic acid elevates thioltransferase
activity in motor cortex presumably through maintenance of thiol
status, because the expression of thioltransferase protein is unaf-
fected (Fig. 5). -Lipoic acid administration has recently been
shown to help maintain mitochondrial integrity and prevent age-
associated mitochondrial oxidative decay (Liu et al., 2002). In
conclusion, we demonstrate that thioltransferase mediates recov-
ery of brain mitochondria from oxidative damage caused by
protein-S-glutathionylation and further provide evidence for an
essential function of thioltransferase during recovery from oxida-
tive damage.
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